Myriad Genetics
Business Services · Utah, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
322 N 2200 W, Salt Lake City, Utah, 8411...Phone Number
(801) 584-3600Website
www.myriad.comRevenue
$806.6 MillionStock Symbol
MYGNIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
6
2
2
4
3
2
About Myriad Genetics
Myriad Genetics, Inc. is a molecular diagnostic testing and precision medicine company headquartered in Salt Lake City, Utah. Founded in 1991, the company discovers, develops, and commercializes genetic and genomic tests that assess disease risk, guide treatment decisions, and monitor disease progression across hereditary cancer, oncology, urology, prenatal health, reproductive health, and mental health. Its offerings include hereditary cancer risk panels, prostate cancer prognostic tests, pharmacogenomic testing for mental health medications, and companion diagnostics designed to work alongside targeted cancer therapies.Explore more
Myriad Genetics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Myriad Genetics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Myriad Genetics recently announced quarterly report
Check out if Myriad Genetics is spiking on competitors!
Check if Myriad Genetics has recently received funding, and reach out quickly before it becomes old news!
Myriad Genetics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Myriad Genetics has new funding data
Product Launch: Get notified when Myriad Genetics launches new products
Click to see if Myriad Genetics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Myriad Genetics
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Myriad Genetics
Compare insights from companies similar to Myriad Genetics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Myriad Genetics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Myriad Genetics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Myriad Genetics.
Myriad Genetics Tech Stack
A closer look at the technologies used by Myriad Genetics
See more technologies
Most Recent Scoops
Hiring Plans
Myriad Genetics has announced the hiring, training, and field placement of over 100 new account executives, primarily supporting the company's cancer care continuum product offerings, with these new sales team members expected to begin driving meaningfully increased volume across the cancer care continuum in 2027 and beyond.
Hiring Plans, Sales, Sales Training
Pain Point
Myriad Genetics is experiencing elevated reimbursement pressure on its MyRisk hereditary cancer test, driven by changing prior authorization requirements, increased medical record requests, and higher payer denial rates, resulting in a step-down in realized average revenue per test; the company notes this friction is payer-initiated and not the result of changes in medical policy.
Pain Point
Earnings
Myriad Genetics has reported that the 9% year-over-year decline in average revenue per test for Q2 included an approximately $11 million headwind from lower-than-expected prior period collections, including a $4 million write-off of aged receivables; excluding this headwind, average revenue per test declined 3% year-over-year, reflecting elevated payer friction for prenatal and hereditary cancer tests in 2026.
Earnings, Accounting, Financial Reporting, Finance
Earnings
Myriad Genetics has reported that its cancer care continuum product category generated revenue of $114.1 million in Q2, down 11% year-over-year, reflecting 6% test volume growth offset by a 15% decline in average revenue per test, with hereditary cancer testing volume growing 8% year-over-year and MyRisk test volume growing 10% year-over-year.
Earnings, Finance
Earnings
Medical Research
Myriad Genetics News & Media
Why Myriad Genetics (MYGN) Stock Is Down Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 6.2% in the afternoon session after Piper Sandler double-downgraded the stock to Underweight, stating that major strategic action is likely needed.Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
Myriad Genetics will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST.Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended adjusted EBITDA guidance. Levi & Korsinsky is investigating potential securities...Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN)
On May 5, 2026, Myriad Genetics management reaffirmed full-year revenue of $860-$880 million. Just three months later, the Company cut guidance to $770-$790 million and adjusted EBITDA guidance was suspended -- and MYGN shareholders absorbed the loss. NEW YORK, Aug. 3, 2026 /PRNewswire/...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Myriad Genetics
Sign Up For FreeTo access detailed company insights
Myriad Genetics, Inc. is a molecular diagnostic testing and precision medicine company headquartered in Salt Lake City, Utah. Founded in 1991, the company discovers, develops, and commercializes genetic and genomic tests that assess disease risk, guide treatment decisions, and monitor disease progression across hereditary cancer, oncology, urology,... Read More
